Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budesonide in BLES refers to a combination of budesonide, a synthetic corticosteroid with potent topical anti-inflammatory activity, and BLES (Bovine Lipid Extract Surfactant). Studies, specifically an in vitro study referenced [5], have examined the effects of budesonide on surfactant properties, including BLES. This study found that budesonide markedly reduced the surface-tension-lowering properties of surfactant preparations, including BLES, particularly at higher concentrations. Budesonide's general mechanism of action involves binding to and activating glucocorticoid receptors (GR) in the cytoplasm, which then translocates to the nucleus to regulate gene expression, reducing inflammation by inhibiting inflammatory genes and activating genes that reduce cytokine formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide in BLES.